risankizumab (Skyrizi)

Following a full submission:

risankizumab (Skyrizi®) is accepted for restricted use within NHSScotland.

Indication under review: for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.

SMC restriction: for patients who have failed to respond to conventional systemic therapies (including ciclosporin, methotrexate and phototherapy), are intolerant to, or have a contraindication to these treatments.

Risankizumab was superior to placebo, a tumour necrosis factor antagonist, and an interleukin 12/23 antagonist in improving symptoms of adult patients with moderate to severe plaque psoriasis.

This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of risankizumab. This SMC advice is contingent upon the continuing availability of the patient access scheme, or a list price that is equivalent or lower, in NHSScotland.